AI healthtech startup BioStack has raised $9.5 million in seed funding led by Peak XV Partners to advance its platform that consolidates fragmented clinical data for medical AI model training and research. The company plans to expand operations in the US, India, Brazil, and Argentina while enhancing its technology and talent base.
- Raised $9.5M seed round led by Peak XV Partners and others
- Expanding presence in the US, India, Brazil, and Argentina
- Processed 100M+ de-identified patient records and clinical images
What happened
BioStack, an AI-powered healthtech startup, recently raised $9.5 million in a seed funding round led by Peak XV Partners and supported by other notable investors including Afore Capital, DCVC, Emerson Collective, SV Angel, Verdict Capital, Streamlined Ventures, and Y Combinator. The funding will be used to expand the company’s footprint internationally and enhance its technology stack.
The company, founded in 2025 by Sanat Mishra and Parth Patwa, develops proprietary training datasets for medical AI by aggregating and harmonizing fragmented clinical data from multiple sources such as electronic health records, medical imaging, clinical notes, and medication information. BioStack services hospitals in the US, Brazil, and Argentina, and connects Indian cancer patients to investigational vaccine programs.
Why it matters
BioStack addresses a critical challenge in healthcare AI by building the infrastructure needed to unify diverse clinical data streams into coherent datasets that support AI model training, medical research, and biotechnology innovation. This work facilitates more accurate AI diagnostics, disease modeling, patient stratification, and treatment response evaluation.
In addition to providing custom workflows to safeguard patient privacy through de-identification, BioStack has processed over 100 million anonymized patient records, several hundred thousand imaging scans, and millions of telehealth transcripts. This scale highlights the growing importance of robust, privacy-centric clinical data platforms in advancing medical AI across multiple international markets.
What to watch next
BioStack’s next steps include scaling its engineering and research teams to accelerate product development and expand its market reach in the US, India, Brazil, and Argentina. The startup’s role in connecting clinical data with AI innovation places it as a key player in the evolving medical AI ecosystem, especially given India’s growing position in AI data collection and training dataset markets.
Given the global interest in AI healthcare solutions and burgeoning datasets in India, BioStack’s progress will be important to follow as it potentially collaborates with technology firms, research institutions, and healthcare providers to enhance AI-driven medical outcomes. An increasing focus on data privacy and regulatory compliance will also shape its future offerings and partnerships.